Copyright: ©Author(s) 2026.
World J Psychiatry. Sep 19, 2026; 16(9): 121407
Published online Sep 19, 2026. doi: 10.5498/wjp.121407
Published online Sep 19, 2026. doi: 10.5498/wjp.121407
Table 4 Risk stratification based on number of elevated biomarkers, mean ± SD
| Number of elevated biomarkers | n | Anxiety-depression incidence (%) | Mean HADS | OR (95%CI) | P value |
| 0 (low risk) | 58 | 13.8 | 6.2 ± 2.8 | Reference | - |
| 1 (intermediate risk) | 130 | 36.9 | 11.8 ± 4.6 | 3.42 (1.38-8.48) | 0.008 |
| 2 (high risk) | 82 | 76.2 | 18.4 ± 5.2 | 19.58 (7.32-52.34) | < 0.001 |
| P for trend | - | - | - | - | < 0.001 |
- Citation: Xu GW, Zhu XL, Yin CH. Serum NfL and GFAP levels and their association with anxiety-depression in Alzheimer’s disease patients: A clinical retrospective study. World J Psychiatry 2026; 16(9): 121407
- URL: https://www.wjgnet.com/2220-3206/full/v16/i9/121407.htm
- DOI: https://dx.doi.org/10.5498/wjp.121407